Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-05-01Clinical Trial Update: Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041) [NA]
This completed Merck Sharp & Dohme-sponsored clinical trial (NCT00211601) evaluated chemotherapy and patient health outcomes for chemotherap…
-
FDA approval · 2015-04-29FDA Approved: AKYNZEO — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved a supplemental application for AKYNZEO (netupitant and palonosetron) to modify its labeling for prevention of chemotherapy-indu…
-
FDA approval · 2015-04-27FDA Approved: AKYNZEO — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
The FDA approved a supplemental application for AKYNZEO (netupitant and palonosetron) from Helsinn Therapeutics (U.S.), Inc., likely affecti…
-
CLINICAL_TRIALS withdrawal · 2015-04-17Clinical Trial Update: A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy [Phase 3]
A Phase 3 trial evaluating IV casopitant to prevent nausea and vomiting caused by cisplatin-based chemotherapy has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2015-04-16Clinical Trial Update: Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy [Phase 2]
Phase 2 clinical trial update from GlaxoSmithKline on preventing chemotherapy-induced nausea and vomiting caused by moderately emetogenic ch…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-04-03FDA Approved: ONDANSETRON — Supplemental Application (Qilu Pharmaceutical Co., Ltd.)
FDA approved a supplemental application for ondansetron from Qilu Pharmaceutical Co., Ltd. (ANDA 203711), authorizing a supplemental submiss…
-
FDA approval · 2015-03-30FDA Approved: CESAMET — Supplemental Application (Bausch Health US LLC)
FDA approves a supplemental application for CESAMET (nabilone) from Bausch Health US LLC.
-
FDA approval · 2015-03-18FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for ondansetron hydrochloride by Sun Pharmaceutical Industries, expanding its approved use.
-
CLINICAL_TRIALS trial_result · 2015-03-10Clinical Trial Update: Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer [Phase 2, Phase 3]
This clinical trial update reports Phase 2 and Phase 3 results evaluating ginger for chemotherapy-induced nausea and vomiting in cancer pati…
-
FDA approval · 2015-03-02FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for ondansetron hydrochloride from Hikma Pharmaceuticals USA Inc., related to a generic product.
-
CLINICAL_TRIALS research · 2015-02-23Clinical Trial Update: The Effect of Acupuncture in Chemotherapy-induced Nausea and Vomiting [NA]
This clinical trial update discusses evaluating acupuncture for chemotherapy-induced nausea and vomiting, sponsored by Beijing Hospital of T…
-
FDA approval · 2015-02-16FDA Approved: AKYNZEO — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved a supplemental application for AKYNZEO (netupitant and palonosetron) from Helsinn Therapeutics (U.S.), expanding its indication…
-
CLINICAL_TRIALS trial_result · 2015-01-27Clinical Trial Update: Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients [Phase 2]
Phase 2 randomized crossover PK study comparing subcutaneous versus intravenous granisetron in cancer patients undergoing chemotherapy, eval…
-
CLINICAL_TRIALS trial_result · 2015-01-27Clinical Trial Update: Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy [Phase 1, Phase 2]
This update summarizes a Phase 1/2 pharmacokinetic study comparing subcutaneous versus intravenous palonosetron for chemotherapy-induced nau…
-
CLINICAL_TRIALS trial_result · 2015-01-19Clinical Trial Update: Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy [Phase 3]
Phase 3 trial comparing aprepitant to placebo for prevention of chemotherapy-induced nausea and vomiting in children and adolescents; the st…
-
FDA approval · 2015-01-17FDA Approved: ONDANSETRON — Supplemental Application (Eugia US LLC)
The FDA approved a supplemental application for ondansetron hydrochloride from Eugia US LLC (ANDA 202599), granting regulatory approval for …
-
FDA approval · 2015-01-15FDA Approved: ONDANSETRON — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for ondansetron filed by PAI Holdings dba PAI Pharma.
-
FDA approval · 2015-01-15FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for ondansetron hydrochloride from Aurobindo Pharma Limited, enabling the generic product to adv…
-
FDA approval · 2015-01-14FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC.)
FDA approved a supplemental application for ondansetron hydrochloride from Chartwell RX, LLC., indicating approval of an additional formulat…
-
FDA approval · 2015-01-12FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for EMEND (fosaprepitant dimeglumine) from Merck Sharp & Dohme LLC, updating its labeling for preven…
-
FDA approval · 2015-01-12FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for EMEND (aprepitant) by Merck Sharp & Dohme LLC, updating the product's labeling and indications.
-
FDA approval · 2015-01-09FDA Approved: ONDANSETRON — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for ondansetron supplied by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. (ANDA 0792…
-
FDA approval · 2014-12-31FDA Approved: ONDANSETRON — Supplemental Application (ACTAVIS PHARMA, INC.)
FDA approved a supplemental application for ondansetron from Actavis Pharma, updating the approved product under the existing NDA.
-
FDA approval · 2014-12-21FDA Approved: ONDANSETRON — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approves a supplemental application for ondansetron (generic) by Rising Pharma Holdings, Inc., adding another approved generic version.
-
FDA approval · 2014-12-20FDA Approved: ONDANSETRON — Supplemental Application (Taro Pharmaceuticals U.S.A., Inc.)
FDA approved a supplemental application for ondansetron hydrochloride (ONDANSETRON) from Taro Pharmaceuticals U.S.A., Inc.